Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dendritic cells for specific cancer immunotherapy
Autore:
Meidenbauer, N; Andreesen, R; Mackensen, A;
Indirizzi:
Univ Regensburg, Dept Hematol Oncol, D-93042 Regensburg, Germany Univ Regensburg Regensburg Germany D-93042 , D-93042 Regensburg, Germany
Titolo Testata:
BIOLOGICAL CHEMISTRY
fascicolo: 4, volume: 382, anno: 2001,
pagine: 507 - 520
SICI:
1431-6730(200104)382:4<507:DCFSCI>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
T-LYMPHOCYTE RESPONSES; COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING CELLS; HUMAN PERIPHERAL-BLOOD; HEMATOPOIETIC PROGENITOR CELLS; EXOGENOUS SOLUBLE-ANTIGEN; MEDIATED GENE-TRANSFER; SERUM-FREE CONDITIONS; GENERATED IN-VITRO; C-KIT-LIGAND;
Keywords:
antigen presenting cells; T cells; tumor immunotherapy; vaccination;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
161
Recensione:
Indirizzi per estratti:
Indirizzo: Mackensen, A Univ Regensburg, Dept Hematol Oncol, D-93042 Regensburg, Germany Univ Regensburg Regensburg Germany D-93042 ensburg, Germany
Citazione:
N. Meidenbauer et al., "Dendritic cells for specific cancer immunotherapy", BIOL CHEM, 382(4), 2001, pp. 507-520

Abstract

The characterization of tumor-associated antigens recognized by human T lymphocytes in a major histocompatibility complex (MHC)-restricted fashion has opened new possibilities for immunotherapeutic approaches to the treatment of human cancers. Dendritic cells (DC) are professional antigen presenting cells that are well suited to activate T cells toward various antigens, such as tumor-associated antigens, due to their potent costimulatory activity. The availability of large numbers of DC, generated either from hematopoietic progenitor cells or monocytes in vitro or isolated from peripheral blood, has profoundly changed pre-clinical research as well as the clinical evaluation of these cells. Accordingly, appropriately pulsed or transfected DC may be used for vaccination in the field of infectious diseases or tumor immunotherapy to induce antigen-specific T cell responses. These observations led to pilot clinical trials of DC vaccination for patients with cancer in order to investigate the feasibility, safety, as well as the immunologicand clinical effects of this approach. Initial clinical studies of human DC vaccines are generating encouraging preliminary results demonstrating induction of tumor-specific immune responses and tumor regression. Nevertheless, much work is still needed to address several variables that are criticalfor optimizing this approach and to determine the role of DC-based vaccines in tumor immunotherapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/20 alle ore 12:54:12